Published in J Invest Dermatol on March 01, 1983
In vivo and in vitro effects of glucocorticoids on lectin-induced blastogenesis in atopic dermatitis. Arch Dermatol Res (1991) 0.75
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med (1973) 3.15
Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol (2001) 2.80
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol (2014) 2.76
Human monocytes and macrophages. Interaction with antigen and lymphocytes. J Cell Biol (1970) 2.35
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest (1975) 2.04
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science (1994) 1.99
Serologic tests for syphilis and the false-positive reactor. Arch Dermatol (1966) 1.95
Cyclosporine improves psoriasis in a double-blind study. JAMA (1986) 1.95
Fluorescent treponemal-antibody absorption tests. Studies of false-positive reactions to tests for syphilis. N Engl J Med (1967) 1.91
Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest (1993) 1.87
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol (1998) 1.87
Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Arch Dermatol (1993) 1.86
The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol (2000) 1.80
The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor). J Exp Med (1971) 1.65
Plasma prekallikrein: isolation, characterization, and mechanism of activation. J Exp Med (1972) 1.62
Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol (1989) 1.60
Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol (1993) 1.55
Prekallikrein deficiency in man. J Exp Med (1973) 1.53
Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med (1993) 1.52
Cyclosporine in dermatology. J Am Acad Dermatol (1989) 1.50
Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol (1998) 1.50
Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest (1975) 1.49
Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol (2000) 1.46
Activation of the alternative (properdin) pathway of complement by Candida albicans and related species. J Invest Dermatol (1976) 1.45
IL-12 synthesis by human Langerhans cells. J Immunol (1996) 1.43
Photocontact dermatitis to halogenated salicylanilides and related compounds. A clinical and histological review of 26 patients. Arch Dermatol (1968) 1.41
A pilot study of the effect of oral 8-methoxypsoralen and intraarticular ultraviolet light on rheumatoid synovitis. J Rheumatol (1995) 1.40
Cutaneous responses to human C 3 anaphylatoxin in man. Clin Exp Immunol (1972) 1.39
Lymphocytic infiltrates of the skin in association with cyclosporine therapy. J Am Acad Dermatol (1990) 1.39
Immunosuppression in a homosexual man with Kaposi's sarcoma. J Am Acad Dermatol (1982) 1.38
Olecranon and pretibial bursitis in atopic dermatitis: coincidence or association? J Am Acad Dermatol (1994) 1.38
Expression of OKM5 antigen on epidermal cells in mycosis fungoides plaque stage. J Invest Dermatol (1988) 1.38
Melanophages in inflammatory skin disease demonstrate the surface phenotype of OKM5+ antigen-presenting cells and activated macrophages. J Am Acad Dermatol (1988) 1.38
Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol (1998) 1.36
Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol (1990) 1.33
In vitro studies on granulomatous hypersensitivity to beryllium. J Invest Dermatol (1970) 1.33
Immunodeficiencies in severe atopic dermatitis. Depressed chemotaxis and lymphocyte transformation. Arch Dermatol (1976) 1.24
Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol (1995) 1.23
Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis (1999) 1.20
Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol (1978) 1.19
Secular change in the occurrence of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) (1992) 1.19
Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance. J Exp Med (1998) 1.18
Surface morphology of human mononuclear phagocytes during maturation and phagocytosis. J Ultrastruct Res (1974) 1.17
Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells. J Invest Dermatol (1989) 1.17
Studies of immune and normal opsonins during experimental staphylococcal infection in rabbits. J Immunol (1969) 1.16
Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol (1977) 1.16
Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A. Arch Dermatol Res (1989) 1.15
Experimental cutaneous candidiasis in rodents. J Invest Dermatol (1976) 1.15
Effect of plasma kallikrein on coagulation in vitro. Proc Soc Exp Biol Med (1972) 1.15
Characterization of lymphocytes in bronchial lavage fluid from monkeys. J Immunol (1976) 1.14
A frequent tyrosinase gene mutation in classic, tyrosinase-negative (type IA) oculocutaneous albinism. Proc Natl Acad Sci U S A (1990) 1.14
Cutaneous dermal Ia+ cells are capable of initiating delayed type hypersensitivity responses. J Invest Dermatol (1990) 1.13
Atopic dermatitis. J Allergy Clin Immunol (1984) 1.13
Keratolinin: the soluble substrate of epidermal transglutaminase from human and bovine tissue. Proc Natl Acad Sci U S A (1984) 1.13
CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J Immunol (1994) 1.12
Yellow mutant albinism: cytochemical, ultrastructural, and genetic characterization suggesting multiple allelism. Am J Hum Genet (1980) 1.11
Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol (1990) 1.10
Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol (1991) 1.09
Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. J Invest Dermatol (1992) 1.09
Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest (1992) 1.09
Newer concepts of atopic dermatitis. Arch Dermatol (1977) 1.08
Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. J Am Acad Dermatol (1987) 1.08
Isolation and purification of a pemphigus vulgaris antigen from human epidermis. J Clin Invest (1984) 1.07
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol (2001) 1.07
Levamisole therapy in atopic dermatitis: randomized double-blind evaluation. Arch Dermatol (1978) 1.07
Erythropoietic protoporphyria. A clinical and genetic study. JAMA (1970) 1.05
Antigen-presenting OKM5+ melanophages appear in human epidermis after ultraviolet radiation. J Invest Dermatol (1986) 1.05
Immunological reactivity in dermatophytosis. Br J Dermatol (1974) 1.05
The interaction of Hageman factor and immune complexes. J Clin Invest (1972) 1.04
Reversal of immunosuppression inducible through ultraviolet-exposed skin by in vivo anti-CD11b treatment. J Immunol (1996) 1.04
T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol (1993) 1.03
Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol (1986) 1.03
Concurrent eosinophilic fasciitis and cutaneous T-cell lymphoma. Eosinophilic fasciitis as a paraneoplastic syndrome of T-cell malignant neoplasms? Arch Dermatol (1991) 1.03
Isolation, purification and characterization of bovine epidermal transglutaminase. Biochim Biophys Acta (1976) 1.03
Monocyte induction of IL-10 and down-regulation of IL-12 by iC3b deposited in ultraviolet-exposed human skin. J Immunol (1998) 1.02
Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol (1993) 1.02
Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol (1990) 1.02
Oral therapy with ketoconazole for dermatophyte infections unresponsive to griseofulvin. Rev Infect Dis (1981) 1.01
Experimental cutaneous candidiasis in rodents; II. Role of the stratum corneum barrier and serum complement as a mediator of a protective infalmmatory response. Arch Dermatol (1978) 1.01
Ketoconazole in griseofulvin-resistant dermatophytosis. J Am Acad Dermatol (1982) 1.01
Solar ultraviolet radiation and the risk of infectious disease: summary of a workshop. Photochem Photobiol (1995) 1.00
Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. Br J Dermatol (2009) 1.00
Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med (1993) 1.00
Erythema multiforme: immune complex vasculitis of the superficial cutaneous microvasculature. J Invest Dermatol (1978) 0.99
Cushing's syndrome with adrenal medullary insufficiency and adrenal autoantibodies. Lancet (1966) 0.99
Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol (1982) 0.99
Purification of a mannan from Candida albicans which activates serum complement. J Invest Dermatol (1979) 0.98
Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol (1993) 0.98
Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA (1991) 0.98
Purification and characterization of a staphylococcal epidermolytic toxin. Infect Immun (1976) 0.98
Cutaneous extramedullary plasmacytomas. Arch Dermatol (1969) 0.97
The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J Invest Dermatol (1998) 0.97